Lord Patel (CB)

My Lords, I am pleased to take part in this short debate. All the important issues were covered by the noble Baroness, Lady Bloomfield, in her brilliant, comprehensive speech—but not by me, as they say, so I will repeat them. The noble Baroness is right that it is time urgently to address this issue. The point has already been made that we increasingly need these radioisotopes as medical advances occur, particularly in molecular radiotherapy, which the noble Baroness did not mention. Molecular radiotherapy is used as internal therapy for diseased organs, as opposed to external radiation, which is what we are all familiar with. We all know that one in two people are going to get cancer. The monitoring of cancers—for example, prostate cancers—requires a particular kind of radioisotope tracer to identify whether there are any metastases. This is now in short supply because we rely on a supply chain that comes from overseas. Basically, there are two nuclear imaging modalities: SPECT, single-photon emission computed tomography, and PET, positron emission tomography. SPECT imaging relies primarily on reactor-produced isotopes, and we have to completely import them because we do not have a reactor. PET relies on cyclotron-produced images. While we have that facility, we do not have it extensively, so we often have to rely on overseas supply chains. I will put it in the context of a patient. The overall problem is that they are waiting for a diagnosis, but cannot have it made because the supply chain for radioisotopes is in short supply or has been held up, and their appointment is cancelled. They wait another few weeks before that appointment is made again, during which time the patient’s cancer grows. Alternatively, they are relying on finding out how the cancer is progressing following diagnosis, particularly to see whether the cancer is responding if treatment is being given, and imaging facilities are needed, but the tracer or isotope is not available. There is a further issue: if we have our own reactor that can be used for research, we will innovate for newer radioisotopes for both diagnosis and treatment. Our scientists are good enough; in fact, they are world leading. Furthermore, most tissues in the body are specific to certain chemical agents. For instance, iodine is used for the thyroid. If we want to diagnose or treat thyroid cancer using internal therapy, we would have a tracer with iodine to target thyroid tumours. Glucose is similarly used for brain tumours, and for identifying cancers that an MRI sometimes will not see. With a particular kind of tracer, PET-CT scans will see them, and therefore diagnosis and treatment happen earlier. I could say this in one sentence or half an hour of speech, but the message would be the same. We urgently need UK-based radioisotope reactor facilities that produce tracers using radioisotopes, and also a cyclotron facility, so that the whole UK can then rely on our own supply. It also enables our researchers to further innovate for new tracers, and therefore end up leading the world. I say to the Minister that the time is now. Can we have the plan, please? Whether it is in Wales or not—I might have been tempted to say Scotland—the ARTHUR project has already made a good business case and worked this out. The cost is not enormous, particularly in the context of the NHS budget and the benefits that the NHS will derive. I plead for the same as the noble Baroness, Lady Bloomfield.